Correlation Between Lyell Immunopharma and Inhibrx
Can any of the company-specific risk be diversified away by investing in both Lyell Immunopharma and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyell Immunopharma and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyell Immunopharma and Inhibrx, you can compare the effects of market volatilities on Lyell Immunopharma and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyell Immunopharma with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyell Immunopharma and Inhibrx.
Diversification Opportunities for Lyell Immunopharma and Inhibrx
0.09 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Lyell and Inhibrx is 0.09. Overlapping area represents the amount of risk that can be diversified away by holding Lyell Immunopharma and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Lyell Immunopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyell Immunopharma are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Lyell Immunopharma i.e., Lyell Immunopharma and Inhibrx go up and down completely randomly.
Pair Corralation between Lyell Immunopharma and Inhibrx
Given the investment horizon of 90 days Lyell Immunopharma is expected to generate 1.6 times more return on investment than Inhibrx. However, Lyell Immunopharma is 1.6 times more volatile than Inhibrx. It trades about 0.01 of its potential returns per unit of risk. Inhibrx is currently generating about -0.01 per unit of risk. If you would invest 62.00 in Lyell Immunopharma on December 29, 2024 and sell it today you would lose (3.00) from holding Lyell Immunopharma or give up 4.84% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Lyell Immunopharma vs. Inhibrx
Performance |
Timeline |
Lyell Immunopharma |
Inhibrx |
Lyell Immunopharma and Inhibrx Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Lyell Immunopharma and Inhibrx
The main advantage of trading using opposite Lyell Immunopharma and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyell Immunopharma position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.Lyell Immunopharma vs. Cullinan Oncology LLC | Lyell Immunopharma vs. Monte Rosa Therapeutics | Lyell Immunopharma vs. Revolution Medicines | Lyell Immunopharma vs. Nkarta Inc |
Inhibrx vs. Day One Biopharmaceuticals | Inhibrx vs. Mirum Pharmaceuticals | Inhibrx vs. Rocket Pharmaceuticals | Inhibrx vs. Avidity Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |